At ESMO Congress 2019, one of the Patient Advocacy sessions addressed a key issue in the management of non-small cell lung cancer, i.e. having a common cancer split into different subgroups. With more molecular target…
Watch Here
Final overall survival (OS) data from FLAURA trial presented at ESMO Congress 2019 confirm that osimertinib is an option for first-line treatment of patients with EGFR-mutated NSCLC, as reported by Prof. Martin Reck from Prof….
Watch Here
Conflicting results from two analyses presented yesterday at ESMO Congress 2019 give more cloud than clarity regarding the role of tTMB as a predictive biomarker for pembrolizumab in non-small-cell lung cancer (NSCLC). The first of…
Read More
The place of ceritinib as a standard treatment option for patients with ALK+ non-small-cell lung cancer (NSCLC) and active brain metastases (BM) has been confirmed by the ASCEND-7 trial. These results will be presented as…
Read More
At ESMO Congress 2019, phase III FLAURA trial is one of the much awaited studies in lung cancer, according to Alessandra Curioni Fontecedro, University Hospital Zürich, Switzerland and Associate Editor of the Daily Reporter. Overall…
Watch Here
